PHARMACEUTICAL FORMULATION CONTAINING REMDESIVIR AND ITS ACTIVE METABOLITES FOR DRY POWDER INHALATION
The invention provides a pharmaceutical composition for dry powder inhalation and a preparation method thereof, wherein the composition comprises, a carrier material, preferably lactose and micronized remdesivir and/or its active metabolites (such as Alanine metabolite (Ala-met), Nucleoside monophosphate, and Nucleoside Triphosphate (NTP)) and/or its analog GS-441524 and pharmaceutically acceptable salts thereof. The active pharmaceutical ingredient may be an anti-viral, taken as remdesivir and/or its active metabolites (such as Alanine metabolite (Ala-met), Nucleoside monophosphate. and Nucleoside Triphosphate (NTP)) and/or its analog GS-441524. The dry powder inhalation containing Remdesivir and/or its active metabolites and/or its analog GS-441524 as active ingredients, further consisting of a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation deep into the lungs for the treatment of respiratory disorders. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, an active ingredient, including, small organic molecules, including, remdesivir and/or its active metabolites (such as Alanine metabolite (Ala-met), Nucleoside monophosphate, and Nucleoside Triphosphate (NTP)) and/or its analog GS-441524 and pharmaceutically acceptable salts thereof for the treatment of disease and disorders, for example, COVID-19 and other viral respiratory infections.
1 . A dry powder pharmaceutical formulation for administration by inhalation comprising:
(a) microparticles of an active substance selected from the group consisting of remdesivir, active metabolites of remdesivir, remdesivir's analog GS-441524, and combinations thereof; and
(b) microparticles of a pharmacologically acceptable carrier, wherein the microparticles of the active substance thereof have a mass median diameter of between about 1 μm and about 6 μm, and wherein the microparticles of the carrier have a mass median diameter of between about 10 μm and about100 μm.
2 . The pharmaceutical formulation of claim 1 , wherein the active substance is present in an amount of from about 1% to about 90% by weight of the formulation.
3 . The pharmaceutical formulation of claim 1 , wherein the pharmacologically acceptable carrier is lactose monohydrate.
4 . The pharmaceutical formulation of claim 1 , wherein the lactose has a fine lactose fraction with a mass median diameter of less than about 10 μm.
5 . The pharmaceutical formulation of claim 1 , further comprising a ternary agent.
6 . The pharmaceutical formulation of claim 5 , wherein the ternary agent is magnesium stearate.
7 . The pharmaceutical formulation of claim 6 , wherein the magnesium stearate is present in an amount of about 0.6% w/w of the pharmaceutical formulation.
8 . A unit dose form comprising the pharmaceutical formulation of claim 1 .
9 . The unit dose form of claim 8 , wherein the unit dose is selected from the group consisting of a capsule, a cartridge, and a blister pack.
10 . The unit dose form of claim 8 , wherein the active substance is present in an amount of about 1 mg/dose to about 300 mg/dose.
11 . The unit dose form of claim 8 , wherein the active substance is present in an amount of about 10 mg per dose to 100 mg/dose.
12 . The unit dose form of claim 8 , wherein the active substance is present in an amount of selected from about 12.5 mg/dose, about 25 mg/dose, and about 50 mg/dose.
13 . (canceled)
14 . (canceled)
15 . The pharmaceutical formulation of claim 1 , further comprising a surface active agent.
16 . A device for administering an active substance selected from the group consisting of remdesivir, active metabolites of remdesivir, and combinations thereof comprising microparticles comprising the active substance and a pharmacologically acceptable carrier,
wherein the microparticles of remdesivir, active metabolites of remdesivir, and combinations thereof have a mass median diameter of between about 1 and about 10 μm, and
wherein the microparticles are contained in a medicament dispenser selected from the group consisting of a reservoir dry powder inhaler, a unit-dose dry powder inhaler, a pre-metered multi-dose dry powder inhaler, a nasal inhaler, and a pressurized metered dose inhaler.
17 . A pharmaceutical formulation for administration by inhalation comprising:
(i) microparticles of an active substance selected from the group consisting of remdesivir, active metabolites of remdesivir and combinations thereof;
(ii) a pharmacologically acceptable carrier,
wherein the microparticles of the active substance have a mass median diameter of between about 1 and about 10 μm, and
(iii) a propellant
wherein the microparticles are suspended in the propellant.
18 . The pharmaceutical formulation of claim 17 , wherein the propellant is selected from the group consisting of a fluorocarbon and hydrogen-containing chlorofluorocarbon.
19 . The pharmaceutical formulation of claim 18 , wherein the propellant is a hydrofluoroalkane.
20 . The pharmaceutical formulation of claim 18 , wherein the propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane; 1,1,1,2,3,3,3-heptafluoro-n-propane; and mixtures thereof.
21 . The pharmaceutical formulation of claim 17 , further comprising a surface active agent.
22 . The pharmaceutical formulation of claim 17 , wherein the microparticles of the active substance have a mass median diameter of between about 3 and about 7 μm.
23 . A method of treating a virus infection in a patient comprising administering to the patient the pharmaceutical formulation of claim 1 by oral inhalation or nasal inhalation.
24 . The method of claim 23 , wherein the active substance is administered at a daily dose ranging from about 10 mg to about 500 mg.
25 . The method of claim 24 , wherein the active substance is administered at a daily dose ranging from about 50 mg to about 300 mg.
26 . The method of claim 23 , wherein the virus is selected from the group consisting of Ebola and Marburg virus (Filoviridae); coronavirus, new coronavirus COVID-19, Ross River virus, chikungunya virus, Sindbis virus, eastern equine encephalitis virus (Togaviridae, Alphavirus), vesicular stomatitis virus (Rhabdoviridae, Vesiculovirus), Amapari virus, Pichindé virus, Tacaribe virus, Junin virus, Machupo virus (Arenaviridae, Mammarenavirus), West Nile virus, dengue virus, yellow fever virus (Flaviviridae, Flavivirus); human immunodeficiency virus type 1 (Retroviridae, Lentivirus); Moloney murine leukemia virus (Retroviridae, Gammaretrovirus); respiratory syncytial virus (Paramyxoviridae, Pneumovirinae, Pneumovirus); vaccinia virus (Poxviridae, Chordopoxvirinae, Orthopoxvirus); herpes simplex virus type 1, herpes simplex virus type 2 (Herpesviridae, Alphaherpesvirinae, Simplexvirus); human cytomegalovirus (Herpesviridae, Betaherpesvirinae, Cytomegalovirus); Autographa californica nucleopolyhedrovirus (Baculoviridae, Alphabaculoviridae) (an insect virus); Semliki Forest virus, O'nyong-nyong virus, rubella (German measles) virus (Togaviridae, Rubivirus); rabies virus, Lagos bat virus, Mokola virus (Rhabdoviridae, Lyssavirus); Guanarito virus, Sabia virus, Lassa virus (Arenaviridae, Mammarenavirus); Zika virus, Japanese encephalitis virus, St. Louis encephalitis virus, tick-borne encephalitis virus, Omsk hemorrhagic fever virus, Kyasanur Forest virus (Flaviviridae, Flavivirus); human hepatitis C virus (Flaviviridae, Hepacivirus); influenza A/B virus (Orthomyxoviridae, the common ‘flu’ virus); Hendra virus, Nipah virus (Paramyxoviridae, Paramyxovirinae, Henipavirus); measles virus (Paramyxoviridae, Paramyxovirinae, Morbillivirus); variola major (smallpox) virus (Poxviridae, Chordopoxvirinae, Orthopoxvirus); human hepatitis B virus (Hepadnaviridae, Orthohepadnavirus); Middle East Respiratory Syndrome (MERS) virus, severe acute respiratory syndrome CoV (SARS-CoV), Marburg virus, and hepatitis delta virus (hepatitis D virus).
27 . A method of treating a virus infection in a patient comprising administering to the patient the pharmaceutical formulation of claim 17 by oral inhalation or nasal inhalation.
28 . The method of claim 27 , wherein the active substance is administered at a daily dose ranging from about 10 mg to about 500 mg.
29 . The method of claim 28 , wherein the active substance is administered at a daily dose ranging from about 50 mg to about 300 mg.
30 . The method of claim 27 , wherein the virus is selected from the group consisting of Ebola and Marburg virus (Filoviridae); coronavirus, new coronavirus COVID-19, Ross River virus, chikungunya virus, Sindbis virus, eastern equine encephalitis virus (Togaviridae, Alphavirus), vesicular stomatitis virus (Rhabdoviridae, Vesiculovirus), Amapari virus, Pichindé virus, Tacaribe virus, Junin virus, Machupo virus (Arenaviridae, Mammarenavirus), West Nile virus, dengue virus, yellow fever virus (Flaviviridae, Flavivirus); human immunodeficiency virus type 1 (Retroviridae, Lentivirus); Moloney murine leukemia virus (Retroviridae, Gammaretrovirus); respiratory syncytial virus (Paramyxoviridae, Pneumovirinae, Pneumovirus); vaccinia virus (Poxviridae, Chordopoxvirinae, Orthopoxvirus); herpes simplex virus type 1, herpes simplex virus type 2 (Herpesviridae, Alphaherpesvirinae, Simplexvirus); human cytomegalovirus (Herpesviridae, Betaherpesvirinae, Cytomegalovirus); Autographa californica nucleopolyhedrovirus (Baculoviridae, Alphabaculoviridae) (an insect virus); Semliki Forest virus, O'nyong-nyong virus, rubella (German measles) virus (Togaviridae, Rubivirus); rabies virus, Lagos bat virus, Mokola virus (Rhabdoviridae, Lyssavirus); Guanarito virus, Sabia virus, Lassa virus (Arenaviridae, Mammarenavirus); Zika virus, Japanese encephalitis virus, St. Louis encephalitis virus, tick-borne encephalitis virus, Omsk hemorrhagic fever virus, Kyasanur Forest virus (Flaviviridae, Flavivirus); human hepatitis C virus (Flaviviridae, Hepacivirus); influenza A/B virus (Orthomyxoviridae, the common ‘flu’ virus); Hendra virus, Nipah virus (Paramyxoviridae, Paramyxovirinae, Henipavirus); measles virus (Paramyxoviridae, Paramyxovirinae, Morbillivirus); variola major (smallpox) virus (Poxviridae, Chordopoxvirinae, Orthopoxvirus); human hepatitis B virus (Hepadnaviridae, Orthohepadnavirus); Middle East Respiratory Syndrome (MERS) virus, severe acute respiratory syndrome CoV (SARS-CoV), Marburg virus, and hepatitis delta virus (hepatitis D virus).
31 . The pharmaceutical formulation of claim 1 , wherein the active substance is present in an amount ranging from about 30 mg to about 50 mg, the pharmacologically acceptable carrier is lactose in an amount ranging from about 800 to about 860 mg, the lactose has a mass median diameter of between about 60 μm and 90 μm, and about 4.5% w/w of the lactose has a mass median diameter of less than about 4.5% w/w.